Ocular Pharmacology, Therapeutics and Drug Delivery

From first principles of drug absorption to clinic-ready delivery platforms, this session explains how molecules, biologics, and RNA therapeutics reach target tissues in the eye—and how to prove they work safely and durably. We connect pharmacokinetics, pharmacodynamics, and exposure–response modeling with route selection, dosing intervals, and retreatment rules. You’ll see how formulation science (nanocarriers, hydrogels, microneedles, LNPs), device platforms (implants, depots), and targeting strategies (ligands, peptides, antibodies) are chosen for the cornea, anterior chamber, vitreous, and retina. Regulatory expectations for sterility, extractables/leachables, and particulates are translated into practical study designs, while immunogenicity and inflammation risks are handled with chemistry, analytics, and peri-procedural care. Crucially, we show how to align biomarkers—OCT, OCTA, fields, ERG—with meaningful functional endpoints and patient burden, so dosing plans are defensible and scalable. Ocular Pharmacology, Therapeutics & Drug Delivery also maps how small molecules complement anti-VEGF/biologics and how RNA or gene-modifying payloads can be combined with neuroprotection and rehabilitation for durable benefit. If you’re scanning Ophthalmology Conference for a rigorous home where pipeline teams, pharmacists, clinicians, and engineers can meet, this is your anchor. We emphasize study design quality (IVIVC, PBPK/PK-PD modeling, population methods), quality by design for CMC, and lifecycle thinking—from research-grade to commercial—so ideas cross the translational gap. Finally, we highlight must-have analytics for stability, potency, and degradation pathways and share playbooks for depot longevity, refill strategies, and handling nonresponders. For newcomers, begin with compartment models and sampling constraints in the eye; advanced teams can dive into adaptive dosing algorithms, device–drug combination rules, and label-enabling evidence plans. The throughline is simple: rigorous exposure, reliable effect, manageable risk—delivered with patient-centered intervals and real-world feasibility. For deeper grounding, explore ocular pharmacokinetics as the bridge between beautiful formulations and reliable outcomes.